Biotech News

Absci Appoints Gerry Muhle as Chief Commercial Officer to Build Category-Defining Brands for ABS-201 and Its Broader Pipeline

Absci Corporation (ABSI)Absci CorporationCommercial

Global commercial executive brings a track record of launching prescription biologics and building consumer-driven brands at Galderma, Allergan and GSK VANCOUVER, Wash. and NEW YORK, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company

Related news

Absci Corporation

AI-Enabled Biologic Design Absci combines generative artificial intelligence with high-throughput synthetic biology to design and validate novel biologics. Its integrated platform repeatedly feeds laboratory results back into computational models. ABS-201 ABS-201 is a long-acting antibody against the prolactin receptor. Its...

Recent company news

Stock data

Close
8.16 USD
Market cap
990M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States